Ahmed O. Kaseb, Junichi Shindoh, Yehuda Z. Patt, Robert E. Roses, Giuseppe Zimmitti, Richard D. Lozano, Manal M. Hassan, Hesham M. Hassabo, Steven A. Curley, Thomas A. Aloia, James L. Abbruzzese and Jean-Nicolas Vauthey Modified cisplatin/interferon α-2b/doxorubicin/5-fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinoma Cancer 119
Article first published online: 2 JUL 2013 | DOI: 10.1002/cncr.28209
The PIAF (cisplatin/interferon α-2b/doxorubicin/5-fluorouracil) regimen can be tolerable and achieve high response rate in patients with hepatocellular carcinoma who do not have hepatitis or cirrhosis. With modification of the treatment protocol, the PIAF regimen achieved a high rate of conversion to curative surgery (33%) and prolonged survival (median of 21.3 months) in patients with initially unresectable tumor.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.